Compare SMCI & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMCI | EXAS |
|---|---|---|
| Founded | 1993 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.1B | 19.7B |
| IPO Year | 2006 | 2000 |
| Metric | SMCI | EXAS |
|---|---|---|
| Price | $20.47 | $104.94 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 16 | 17 |
| Target Price | $39.53 | ★ $86.62 |
| AVG Volume (30 Days) | ★ 19.3M | 1.8M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.32 |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $2,484,929,000.00 | $4,144,000.00 |
| Revenue This Year | $90.56 | $15.37 |
| Revenue Next Year | $19.83 | $12.41 |
| P/E Ratio | $35.74 | ★ N/A |
| Revenue Growth | ★ 11.68 | N/A |
| 52 Week Low | $27.61 | $38.88 |
| 52 Week High | $62.36 | $104.02 |
| Indicator | SMCI | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 23.23 | 72.80 |
| Support Level | N/A | $103.10 |
| Resistance Level | $33.60 | N/A |
| Average True Range (ATR) | 1.51 | 0.29 |
| MACD | -0.79 | 0.04 |
| Stochastic Oscillator | 0.87 | 97.61 |
Super Micro Computer Inc provides high-performance server technology services to cloud computing, data centers, high-performance computing, and the Internet of Things embedded markets. Its solutions include servers, storage systems, modular blade servers, workstations, full-rack scale solutions, networking devices, server sub-systems, and server management. These turn-key solutions are designed, developed, validated, and installed for AI datacenters. The company has one operating segment that develops and provides high-performance server solutions based upon a, modular and open-standard architecture. More than half of the firm's revenue is generated in the United States, with the rest coming from Europe, Asia, and other regions.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.